Hyperlipidemia, atherosclerosis, and diabetes.
At present the two different mechanisms underlying the hypertriglyceridemia of diabetes are reasonably well defined. The rationale of therapy has grown from this knowledge. One form of hyperlipidemia is due to the hyperinsulinemia which results from the patient's resistance to insulin. The approach to treatment aims to overcome the insulin resistance. In most patients this is done by treating their obesity. The other form of hypertriglyceridemia results from insulin deficiency and is treated by bringing the patient's diabetes under control. There is strongly suggestive evidence that hypertriglyceridemia may be associated with a high risk of atherosclerosis. The reason for treating hypertriglyceridemia in general, and in the diabetic in particular, is to reduce this risk. However, it must be conceded that, at the moment, there is no information about the effect of lower triglyceride levels on the incidence of atherosclerosis. Hence much epidemiologic research is needed before our rationale for treatment can move from the realm of hope to the realm of definite proof. In the mean time an attack on this and the other risk factors is the best way we have to attempt to prevent the major complication of diabetes, atherosclerosis.
D001161:Arteriosclerosis / Q000150:complications*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000628:therapy; D008079:Lipoproteins, VLDL / Q000097:blood; D010195:Pancreatitis / Q000150:complications; D012306:Risk; D014280:Triglycerides / Q000097:blood
D008079:Lipoproteins, VLDL; D014280:Triglycerides